Bausch Health Companies Inc. Deferred Tax Liabilities, Tax Deferred Income
Bausch Health Companies Inc. (BHC) had Deferred Tax Liabilities, Tax Deferred Income of $28.00 million as of 2017-06-30, per its 10-Q filed 2017-08-08.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Liabilities, Net › Deferred Tax Liabilities, Gross
us-gaap:DeferredTaxLiabilitiesTaxDeferredIncome · last filed 2017-08-08
- 2017-06-30: Deferred Tax Liabilities, Tax Deferred Income $28.00M.
- 2017-03-31: Deferred Tax Liabilities, Tax Deferred Income $26.00M.
- 2016-12-31: Deferred Tax Liabilities, Tax Deferred Income $26.00M.
- 2015-12-31: Deferred Tax Liabilities, Tax Deferred Income $17.00M; Deferred Tax Liabilities, Tax Deferred Income as first filed $16.60M.
| Period end | Deferred Tax Liabilities, Tax Deferred Income | Deferred Tax Liabilities, Tax Deferred Income as first filed |
|---|---|---|
| 2017-06-30 | $28.00M 10-Q · filed 2017-08-08 | |
| 2017-03-31 | $26.00M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $26.00M 10-Q · filed 2017-08-08 | |
| 2015-12-31 | $17.00M 10-K · filed 2017-03-01 | $16.60M 10-K · filed 2016-04-29 |
| 2014-12-31 | $18.70M 10-K · filed 2016-04-29 | $18.80M 10-K · filed 2015-02-25 |
| 2013-12-31 | $19.50M 10-K · filed 2015-02-25 | $19.49M 10-K · filed 2014-02-28 |
| 2012-12-31 | $7.03M 10-K · filed 2014-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |